Cognition and Exercise Training

Metabolic Syndrome Clinical Trial

— COGNEX-2  

Official title:

Cerebral Oxygenation, Cardiac Output,Cognitive Function, and Exercise Training in Patients With Metabolic Syndrome, Coronary Heart Disease and Chronic Heart Failure.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01906957
• Other study ID #: COGNEX-2
• Status: Terminated
• Phase: N/A
• Start date: September 2013
• Est. completion date: September 9, 2022

Study information

• Verified date: September 2022
• Source: Montreal Heart Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of study is to investigate the impact of two different training modalities (high intensity interval training (HIIT) versus moderate intensity continuous exercise training (MICET) on cognitive performance, cerebral oxygenation, cardiac output and physical fitness in older healthy adults, patients with metabolic syndrome, coronary heart disease and heart failure. The investigators hypothesized that HIIT modality will lead to a larger improvement in physical fitness (i.e. VO2peak), cardiovascular parameters (cardiac output and stroke volume) and cognitive performance at rest and during submaximal exercise. The primary endpoint will be the improvement in cognitive performance.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 6
• Est. completion date: September 9, 2022
• Est. primary completion date: September 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

Elderly healthy subjects : with no MetS and no-documented CHD, both males and females, aged>60 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Patients with metabolic syndrome and no-documented CHD, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. MetS will be defined according to recent updated criteria: presence of at least three of five criteria, namely abdominal obesity (waist circumference cut-off depending on the recently published ethnic-based variations, triglycerides > 1.70 mmol/l, decreased HDL-cholesterol (< 1.0 mmol/l in men and < 1.3 mmol/l in women), systolic blood pressure > 130 mmHg or diastolic blood pressure > 85 mmHg, and FPG > 5.6 mmol/l. CHD patients, both males and females, aged > 18 years will be included in the study, should they provide written informed consent and have a sufficient initial physical and intellectual capacities allowing an independent daily living. Moreover, they must have documented CHD (prior myocardial infarction, prior coronary angiography or angioplasty, or documented myocardial ischemia on myocardial scintigraphy). Patients with documented stable chronic heart failure will be recruited if they show the

following inclusion criteria:

• =18 years
• Left ventricular ejection fraction (LVEF) <40% (measured within 6 months of their enrolment by MUGA Scan, echo or radiological ventriculography)
• NYHA functional class I-III
• Optimal therapy at stable doses including a beta-blocker and an ACE inhibitor or ARA for at least 6 weeks prior to investigation (unless documented rationale for variation).
• Able to perform an symptom limited exercise test.
• Capacity and willingness to sign the informed consent form.

Exclusion Criteria:

• For healthy elderly subjects:
• age under 60 years
• lack of expressed written consent
• metabolic syndrome
• coronary heart disease
• chronic systolic heart failure
• resting left ventricular ejection fraction < 40 %
• symptomatic aortic stenosis
• chronic atrial fibrillation
• malignant exertional arrhythmias
• non-cardiopulmonary limitation to exercise (e.g: arthritis or claudication)
• severe exercise intolerance.

For patients with metabolic syndrome:

• lack of expressed written consent
• coronary heart disease
• chronic systolic heart failure
• resting left ventricular ejection fraction < 40 %
• symptomatic aortic stenosis
• chronic atrial fibrillation
• malignant exertional arrhythmias
• non-cardiopulmonary limitation to exercise (e.g: arthritis or claudication)
• severe exercise intolerance. For patients with CHD
• lack of expressed written consent
• recent acute coronary event (< 3 months)
• chronic systolic heart failure
• resting left ventricular ejection fraction < 40 %
• symptomatic aortic stenosis
• severe non-revascularize coronary disease including left main coronary stenosis
• patient awaiting coronary artery bypass surgery
• chronic atrial fibrillation
• presence of permanent ventricular pacemaker
• malignant exertional arrhythmias
• non-cardiopulmonary limitation to exercise (e.g: arthritis or claudication)
• severe exercise intolerance.

For CHF patients:

• Any relative or absolute contraindications to exercise training among patients with stable chronic heart failure according to current recommendations (Working Group on Cardiac Rehabilitation 2001)
• Fixed-rate pacemaker or ICD devices with heart rate limits set lower than the exercise training target heart rate.
• Major cardiovascular event of procedure within the 3 months preceding enrolment in the study.
• Atrial fibrillation
• Heart failure secondary to significant uncorrected primary valvular disease (except for mitral regurgitation secondary to LV dysfunction)
• Heart failure secondary to congenital heart disease or obstructive cardiomyopathy.

Related Conditions & MeSH terms

• Chronic Heart Failure
• Coronary Artery Disease
• Coronary Disease
• Coronary Heart Disease
• Heart Diseases
• Heart Failure
• Metabolic Syndrome
• Myocardial Ischemia
• Syndrome

Intervention

Other:
• high intensity interval training (HIIT)
High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
• moderate intensity continuous exercise training
Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.

Locations

Country	Name	City	State
Canada	Cardiovascular Prevention and Rehabilitation Centre (EPIC), Montreal Heart Institute	Montreal	Quebec
Canada	Cardiovascular Prevention and Rehabilitation Centre, Montreal Heart Institute	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Montreal Heart Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Maximal cardiac output and stroke volume	Maximal cardiac output and stroke volume wil be measured continuously at rest, during exercise and recovery using an impedance cardiography device.	At baselin and after 3 months
Other	Cerebral hemodynamics with NIRS	Cerebral oxygenation/perfusion will be measured using near-infrared spectroscopy (NIRS) system during maximal exercise and recovery.	At baseline and after 3 months
Other	Microvascular function at the forearm level (NIRS)	Microvascular function will be assessed using during reactive hyperemia using near-infra red spectroscopy (NIRS) placed on top of the brachio-radialis muscle.	At baseline and after 3 months
Primary	Cognitive function assessed by standard pen-paper battery test	a) Digit Span (Forward and Backward) (short-term and working memory), b) Digit Symbol Substitution Test (attention & processing speed), c) Trail making test, part A and B (mental flexibility), d) D-KEFS Color-Word Interference Stroop Test (selective attention and inhibition) and e) Rey Auditory Verbal Learning Test (long-term verbal memory).	At baseline and after 3 months
Secondary	Maximal aerobic capacity (VO2max)	Gas exchanges will be measured during maximal incremental test. The highest value reached during the exercise phase of the maximal test (ergocycle) will be considered as the VO2max.	At baseline and after 3 months